FOG-001 + trifluridine + tipiracil + bevacizumab

FOG-001 + trifluridine + tipiracil + bevacizumab is an investigational combination therapy primarily studied in advanced and metastatic colorectal cancer and other solid tumors. **FOG-001** is a first-in-class competitive inhibitor of β-catenin interactions with the T-cell factor (TCF) transcription factors, directly blocking the Wnt/β-catenin pathway, a key oncogenic driver associated with poor prognosis and resistance in many tumors. **Trifluridine** is a thymidine-based nucleoside analogue that induces DNA damage, inhibiting tumor cell growth, while **tipiracil** is a thymidine phosphorylase inhibitor that prevents breakdown of trifluridine, enhancing its efficacy. **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis and thereby limiting tumor blood supply. The combination is being tested for improved efficacy and response rates in patients previously treated or resistant to conventional therapies, leveraging complementary mechanisms: tumor-intrinsic blockade of Wnt signaling (FOG-001), cytotoxic DNA damage (trifluridine), prevention of trifluridine catabolism (tipiracil), and anti-angiogenic activity (bevacizumab)[1][3][5][4][2][6].

Brand names

Lonsurf (for trifluridine + tipiracil)Avastin (for bevacizumab)

Other names

FOG-001 + trifluridine/tipiracil + bevacizumab